ABT · 10-Q · 2026Q3 · Full report

Liquidity and Cash Position

ABBOTT LABORATORIES · 2026-11-04 · Importance 91 · Surprise 88 · Matches filing data

At September 30, 2026, cash and cash equivalents were $4.052 billion, down from $8.522 billion at December 31, 2025. Long-term debt was $29.451 billion and current debt was $1.708 billion, compared with $9.896 billion and $3.033 billion, respectively, at year-end 2025. Abbott issued $20.0 billion of debt in March 2026 to finance the Exact Sciences acquisition, including notes due from 2029 through 2066 with stated fixed rates ranging from 3.700% to 5.600%, plus $1.0 billion of SOFR+50 basis-point notes due 2029. Abbott repaid €1.14 billion of notes, approximately $1.3 billion, at maturity on September 27, 2026.

Key facts

• As of September 30, 2026, Abbott had $4.052 billion in cash and cash equivalents, down from $8.522 billion at December 31, 2025. source
• On September 27, 2026, Abbott repaid the €1.14 billion outstanding principal on its 1.500% Notes at maturity, equivalent to approximately $1.3 billion. source
• Abbott’s cash and cash equivalents decreased from $8.5 billion at December 31, 2025, to $4.1 billion at September 30, 2026, primarily reflecting Exact Sciences acquisition funding, repayment of assumed debt, and other payments, partly offset by operating cash generation. source
• Abbott’s working capital decreased from $9.5 billion at December 31, 2025, to $7.3 billion at September 30, 2026, primarily reflecting lower cash, partly offset by higher receivables and inventories and lower current long-term debt. source
• At September 30, 2026, Abbott’s long-term debt ratings were A+ from S&P Global Ratings and Aa3 from Moody’s Investors Service; Abbott expects to maintain an investment-grade rating. source
• Abbott’s total long-term debt carrying value was $31.159 billion at September 30, 2026, compared with $12.929 billion at December 31, 2025. source

Impact estimates